source Post navigation Dexcom survey shows healthcare providers opt for CGM tech over new medications in Type 2 diabetes – Fierce Biotech SGLT2 Inhibitor Use Not Linked to Postoperative Diabetic Ketoacidosis – Endocrinology Advisor